T he incidence of melanoma and keratinocyte carcinomas (KCs)dwhich comprise squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skindhave been increasing in the United States and worldwide and represent a significant economic burden. [1] [2] [3] [4] [5] High cholesterol level is also common and affects approximately 13% of adults in the United States. 6 Several cellular mechanisms that promote altered cholesterol homeostasis have been associated with cancer development, [7] [8] [9] [10] [11] [12] and high cholesterol level has been associated with increased risk of certain malignancies including prostate cancer. 13, 14 However, the potential relation between high cholesterol level, KCs, and melanoma has not been previously investigated.
Recent estimates from the National Health and Nutrition Examination Survey suggest that 17% of adults in the United States are taking a statin medication. 15 In contrast to the lack of studies on the potential relation between skin cancers and high cholesterol level, there has been some investigation of the relation between skin cancers and statin (3-hydroxy-3 methylglutaryl coenzyme A inhibitor) use.
Although primarily prescribed as cholesterollowering medications, statins have been shown to have pleiotropic properties, which include inhibition of tumor cell growth. [16] [17] [18] [19] Conversely, statins have also been associated immunosuppression and inhibition of the Ras signaling pathway, [20] [21] [22] [23] which has been associated with development of KCs. [24] [25] [26] A large prospective study in women demonstrated no significant association between statin use and risk of melanoma. 27 Previous studies investigating the relation between statin use and KCs found an increased risk of KCs with statin use. [28] [29] [30] [31] However, data from these studies are limited by lack of adjustment for ultraviolet light exposure 28 and lack of malignancy verification and diagnosis date. 29 We prospectively investigated the relation between high cholesterol level, statin use, and risk of melanoma, SCC, and BCC in the Nurses' Health Study (NHS) and the Health Professionals Followup Study (HPFS)d2 cohorts followed by our research group.
MATERIALS AND METHODS

Study participants
The NHS is a prospective cohort of 121,700 female registered nurses who were age 30 to 55 years at study onset in 1976. The HPFS was established when 51,529 male health professionals aged 40 to 75 years were enrolled in 1986. In both cohorts, follow-up questionnaires are administered biennially, with an average follow-up rate of more than 90% of the eligible person-time. This study was approved by the Partners Healthcare Institutional Review Board (1999P011114).
Ascertainment of high cholesterol level
On the 1976 and 1978 NHS questionnaires, participants were asked whether they had an elevated cholesterol level. On the 1980 NHS questionnaire and 1986 HPFS questionnaire, and every 2 years thereafter, participants were asked whether a clinician had diagnosed their cholesterol level as elevated. We classified participants who answered yes to this question as having a history of high cholesterol level from that time onward. A previous validation study in the NHS demonstrated that self-reported cases of elevated cholesterol levels are highly reliable, with more than 85% of reported cases confirmed via review of medical records. 32 
Ascertainment of medication use
In 2000, and every 2 years thereafter, NHS and HPFS participants were asked whether they regularly used statins. We considered women who answered yes to have taken the statins for the previous 2 years. In 2000 participants were also asked the number of years for which they had used statin cholesterollowering drugs before the 2000 questionnaire cycle.
Identification of skin cancer cases
Cohort participants reported new cases of skin cancer biennially. Study physicians reviewed participant medical and pathology reports to verify cases of SCC and melanoma. Although medical records were not obtained for cases of reported BCC, previous validation studies performed in these cohorts have demonstrated approximately 90% accuracy in self-reported BCC cases when confirmed by pathology or medical records.
32,33
Ascertainment of covariates
Covariates were selected on the basis of previously reported related factors for melanoma and KCs. 34 Factors considered included age, natural hair color, number of skin moles, cumulative ultraviolet flux, skin reaction to prolonged sun exposure during childhood/adolescence, number of lifetime severe or blistering sunburns, family history of melanoma, smoking status, body mass index, citrus consumption, 35, 36 and physical activity. Data on covariates were obtained from the biennial questionnaires. Dietary factors were derived from semiquantitative food frequency questionnaires mailed to participants
CAPSULE SUMMARY d
Previous studies demonstrated higher keratinocyte carcinoma risk with statin use but lacked adjustment for important confounders. In this study, longer duration of statin use was associated with higher basal cell carcinoma risk in men only. The relation between statins and skin cancer risk may differ by sex. every 4 years. Physical activity was derived from questionnaire information obtained every 4 years in the NHS, and every 2 years in the HPFS. Timedependent covariates were updated with each questionnaire cycle, when available. In cases in which covariate information was missing, information from the previous questionnaire cycle was carried forward.
Statistical analysis
All analyses were performed in a prospective manner by using information on high cholesterol level and medication use that was collected before the reported case of melanoma or KC. We considered participants who reported a high cholesterol level in or before 2000 (the baseline year of our study) as having a history of high cholesterol level. If on a subsequent questionnaire, participants reported having a high cholesterol level, they were considered to have a history of high cholesterol level from that point onward. Duration of statin use was derived by taking the number of years for which participants reported using statins before the 2000 questionnaire cycle, and assigning 2 additional years of statin use for participants who reported use of statins in any given 2-year time period over the follow-up period. Duration of statin use was categorized as less than 1 year, 1 to 2 years, 3 to 4 years, 5 to 6 years, 7 to 8 years, and more than 8 years of statin use in our SCC and BCC analyses and less than 1 year, 1 to 2 years, 3 to 4 years, and more than 4 years of statin use in our melanoma analyses. A P trend was utilized to test for an overall trend toward significance by increasing categoric duration of statin use.
Multivariable-adjusted relative risks were calculated by using Cox proportional hazards regression models. We examined the relation between high cholesterol level, statin use, and skin cancer by first examining the relation between history of high cholesterol level and skin cancer and subsequently limiting our analysis on statin use and risk of skin cancer to participants with a history of high cholesterol level. We performed a separate analysis investigating high cholesterol level, statin use, and risk of melanoma that did not exclude participants with a history of SCC or BCC at baseline and instead adjusted for a history of SCC or history of BCC in the statistical model. We also ran separate models that included adjustment for use of oral steroid medications. We also performed a secondary analysis to evaluate whether the relation between high serum cholesterol, statin use, and risk of skin cancers varied by health screening among participants. In each questionnaire cycle participants were asked whether they had undergone a physical examination during the past 2 years, and we accounted for their responses in our multivariable models. All P values are 2 sided, with 95% confidence intervals calculated for all relative risks. SAS software (version 9.4, SAS Institute, Inc, Cary, NC) was used to perform all statistical analyses.
RESULTS
Participant characteristics at baseline according to history of high cholesterol level and statin use are shown in Table I (Table II) . Among men, history of high cholesterol level was not associated with risk of any skin cancer; the HR for BCC was 1.08 (95% CI, 1.00-1.16) versus 0.97 for SCC (95% CI, 0.81-1.16) and 1.06 for melanoma (0.71-1.57).
Among participants with a history of high cholesterol level, we did not find significant associations between statin use and risk of BCC, SCC, or melanoma in either women or men (Table III) . In a pooled analysis of the cohorts, the HR was 1.04 for BCC (95% CI, 0.99-1.090 versus 1.08 for SCC (0.94-1.24) and 1.04 for melanoma (0.78-1.38).
Duration of statin use was not associated with risk of BCC (P trend = .86), SCC (P trend = .89), or melanoma (P trend = .68) among women (Table IV) . Longer duration of statin use was associated with increased risk of BCC (P trend = .003) among men. Men who reported statin use for 3 to 4 years, 5 to 6 years, and more than 8 years had an approximately 7%, 12%, and 28% higher risk of BCC, respectively, compared with men who reported less than 1 year of statin use. Duration of statin use was not associated with risk of SCC (P trend = .09) or melanoma among A secondary analysis for melanoma was conducted without exclusion of participants having a history of BCC or SCC at baseline but instead adjusting for history of BCC and SCC, and it did not materially change the results. Accounting for oral steroid use did not materially change our results. Accounting for health screening among participants did not change our results either (data not shown).
DISCUSSION
History of high cholesterol level was not associated with risk of BCC or SCC in women and men. Statin use among participants with a history of high cholesterol level was not associated with risk of SCC, BCC, or melanoma, but there was a significant trend toward higher risk of BCC with longer duration of statin use in men.
High cholesterol level has been associated with increased risk of development of some cancers, including prostate cancer. 13, 14 Cellular mechanisms associated with impaired cholesterol homeostasis have been associated with higher risk of cancer. Inhibition of the ATP binding cassette subfamily A member 1 gene (ABCA1), which in normal cells mediates transfer of cholesterol across the plasma membrane, has been associated with increased CI, Confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; RR, relative risk. *Adjusted for family history of melanoma (yes vs no), natural hair color (red, blonde, light brown, dark brown, or black), number of arm moles (0, 1-2, 3-9, or $10), sunburn susceptibility as a child/adolescent (none/some redness, burn, or painful burn/blisters), number of lifetime blistering sunburns (0, 1-4, 5-9, or $10), cumulative ultraviolet flux since baseline (quintiles), body mass index (\25.0, 25.0-29.9, 30.0-34.9, or $35.0 kg/m 2 ), physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, or $20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use. y The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods by using a random effects model. mitochondrial cholesterol, which inhibits the release of mitochondrial apoptosis-promoting molecules, thus facilitating cancer cell survival. 7 Our data show no association between high cholesterol level and risk of BCC, SCC, or melanoma in the HPFS and NHS.
Previous studies have presented conflicting evidence with regard to the association between statin use and KC, reporting positive, 28-31 negative, [37] [38] [39] or no associations. [40] [41] [42] [43] A recent large epidemiologic study in the Women's Health Initiative demonstrated an increased risk of KC with statin use. 44 However, its data were limited by the self-reported nature of KCs and lack of malignancy diagnosis date. Some studies suggest that statin use may increase risk of KC because of increased regulatory T cells secondary to immunomodulation, [45] [46] [47] and statins have been associated with inhibition of the ras signaling pathway, [20] [21] [22] which has been associated with development of KCs. [24] [25] [26] There is increasing evidence suggesting a higher incidence of KCs among immunosuppressed individuals 48 and thus, that the potential immunosuppressive behavior of statins may serve to increase risk of KCs among statin users. 23 Conversely, statin-induced changes in other cellular pathways have been associated with decreased risk of KC. 16, [49] [50] [51] [52] [53] [54] Our data showed no association between any statin use and risk of BCC, SCC, or melanoma. However, there was a significant trend toward higher risk of BCC with longer duration of statin use in men but no association between risk of , physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, or $20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use. y The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods by using a random effects model. BCC with duration of statin use in women. This finding suggests that there may be differences between the physiologic consequences of long-term statin exposure between men and women. Further, it suggests that the potential effects of statin use may be the result of cumulative, long-term exposure to statins. Statins have been shown to have inhibitory effects on human melanoma cells secondary to inhibition of angiogenesis, cell growth, 18, 19, 55 and promotion of apoptosis. 17, 56 A recent meta-analysis that included data from a number of randomized controlled trials and cohort studies demonstrated no association between statin use and risk of melanoma. 42 Further, a prospective study in postmenopausal women demonstrated no association between statin use and risk of melanoma. 27 In our study, there was no association between statin use or risk of melanoma in men or in women.
Different statins have been shown to have varying degrees of solubility in octanol (lipophilicity) and lipid-lowering potency. [57] [58] [59] [60] A previous study examining the association between statin type and risk of KCs demonstrated higher odds of KC with lovastatin use and simvastatin use than with no statin use in women, which the authors suggested may be related to varying lipophilicity and potency of these drugs. 29 In our study, we found a higher risk of SCC with lovastatin use than with no statin use in men and women, which is consistent with the findings from the previous study. However, we found no association between risk of SCC or BCC with simvastatin use in our study and a lower risk of BCC with pravastatin use than with no statin use in men. These findings suggest that the association between statin use and risk of BCC may differ by statin type.
Our study has limitations. History of high cholesterol level and statin use was self-reported, and we lacked information on duration of statin use before the baseline year. Although we were able to determine duration of statin use, our study lacked information on statin dose in participants. However, data were prospectively collected over 10 years in this study, and information provided by these cohorts has been shown to be highly reliable in previous studies. 32, [61] [62] [63] We adjusted for many potential confounders in our multivariable models, but given the relatively few cases of melanoma in our cohort, the interpretability of our melanoma analyses may be limited. However, it is worth nothing that our findings are consistent with the results from a previous large prospective study on the relation between statin use and risk of melanoma. 27 We limited our analyses to white participants, given the small sample size and lack of skin cancer cases in other ethnic groups.
In conclusion, history of high cholesterol level was not associated with risk of KCs or melanoma, and longer duration of statin use may be associated with higher risk of BCC in men. Our data suggest that there may be differences in the physiologic , and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use. y The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods by using a random effects model. Continued consequences of long-term statin exposure and risk of skin cancers between men and women. Individuals using statins long-term may benefit from counseling on the importance of routine selfsurveillance and health screening. , physical activity (quintiles), smoking status (never, past, or current), total energy intake (quintiles), alcohol (0, 0.1-4.9, 5.0-9.9, 10.0-19.9, or $20.0 g/d), and citrus intake (quintiles). Analyses for women were also adjusted for menopausal status and postmenopausal hormone use. y The multivariate-adjusted hazard ratios from each cohort were combined with meta-analytic methods by using a random effects model.
